Related Experiment Video
Updated: Mar 30, 2026
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure
Haibo Liu1, Xiaofang Guo2, Kang Yao3
1Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; Department of Cardiology, Yinzhou People's Hospital, Medical School of Ningbo University, Ningbo 315040, China.
Insights
Elevated pentraxin-3 (PTX3) levels predict poor prognosis in chronic heart failure (CHF) patients. Higher PTX3 indicates increased risk of cardiac events, including death or rehospitalization, over three years.
Area of Science:
- Cardiology
- Biomarkers
- Prognostic Indicators
Background:
- Chronic heart failure (CHF) is a significant clinical challenge with a need for reliable prognostic markers.
- Pentraxin-3 (PTX3) is an inflammatory marker whose prognostic value in CHF requires further investigation.
Purpose of the Study:
- To evaluate the long-term prognostic significance of plasma pentraxin-3 (PTX3) levels in patients diagnosed with chronic heart failure (CHF).
Main Methods:
- Prospective follow-up of 377 CHF patients for 3 years, monitoring cardiac events (death, rehospitalization).
- Measurement of plasma PTX3 levels and correlation with clinical status (NYHA classification) and cardiac events.
- Statistical analysis including Kaplan-Meier and Cox proportional hazards models to determine independent predictors.
Main Results:
- Plasma PTX3 levels were significantly higher in CHF patients compared to controls and increased with NYHA class.
- Elevated PTX3 levels (≥ 3.64 ng/mL) were associated with a higher incidence of cardiac events.
- Increased PTX3 was identified as an independent risk factor for cardiac events in CHF patients (HR = 4.224, p < 0.01).
Conclusions:
- Plasma PTX3 levels serve as a valuable long-term independent predictor of prognosis in patients with chronic heart failure.
- PTX3 may aid in risk stratification and management decisions for CHF patients.
Abstract:
The aim of this study was to investigate the long-term prognostic value of pentraxin-3 (PTX3) in patients with chronic heart failure (CHF). 377 patients were prospectively followed up for 3 years to determine cardiac events including cardiac death or rehospitalization for worsening heart failure. The plasma PTX3 levels were significantly higher in CHF patients than in healthy subjects (p < 0.001), and they increased with advancing New York Heart Association (NYHA) Functional Classification (p < 0.001). Plasma PTX3 levels in CHF patients with cardiac events were significantly higher than in event-free patients (p < 0.001). We determined the normal upper limit of plasma PTX3 levels from the mean + 2 SD value of 64 control subjects (3.64 ng/mL). A Kaplan-Meier analysis revealed that patients with increased PTX3 (≥ 3.64 ng/mL) were at a higher risk for cardiac events than those without increased PTX3 (p < 0.01). A multifactorial Cox proportional hazards model showed that increased PTX3 ( ≥ 3.64 ngImL) was an independent risk factor for cardiac events in CHF patients (hazard ratio (HR) = 4.224, p < 0.01; 95% CI: 1.130-15.783). Plasma PTX3 levels are a long-term independent predictor of prognosis in patients with CHF.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Heart Failure III: Clinical Manifestations
01:25Pericarditis IV: Nursing Management
01:14Myocarditis III: Medical Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System